Johns Hopkins Bloomburg School of Public Health
While clinical trials of COVID-19 convalescent plasma treatment (CCP) have been ongoing since the pandemic began, doctors have not had good selection criteria for determining those COVID-19 survivors most likely to have strong antibody responses. In a new study co-led by researchers at Johns Hopkins Bloomberg School of Public Health, data collected pointed to sex, age, and severity of disease as being useful in identifying COVID-19 survivors who are likely to have high levels of antibodies.
COVID-19 Healthcare Coalition Response
Researchers and clinicians are working hard to develop immune therapies to treat COVID-19—including the use of convalescent plasma and hyperimmune globulin. This discussion, sponsored by COVID-19 Healthcare Coalition Response, contains discussions by top experts on how these antibody-rich blood products from recovered COVID-19 patients are already impacting care and informing research in monoclonal antibodies and vaccines. Dr. Mark McClellan, Director, Duke-Margolis Center for Health Policy, Robert J. Margolis Professor of Business, Medicine, and Health Policy, Duke University, Former FDA Commissioner, presented on the differences between FDA approvals on therapies versus Emergency Use Authorization. Dr. Nigel Paneth, University Distinguished Professor of Epidemiology & Biostatistics & Pediatrics, Michigan State University, presented on the current studies regarding convalescent plasma effectiveness. Dr. William Mezzanotte, Executive Vice President and Head of R&D, CSL Behring, presented on the current state of using Hyperimmune Globulin (H-IG) as a potential treatment.
Philippe R. Bauer, MD, PhD
Grand Rounds 5/27/2020
The Journal of Clinical Investigation
Guidebook published online April 7 in the Journal of Clinical Investigation to help hospitals scale up ability to deliver blood plasma therapy.